176 related articles for article (PubMed ID: 2415692)
1. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
Order SE; Stillwagon GB; Klein JL; Leichner PK; Siegelman SS; Fishman EK; Ettinger DS; Haulk T; Kopher K; Finney K
J Clin Oncol; 1985 Dec; 3(12):1573-82. PubMed ID: 2415692
[TBL] [Abstract][Full Text] [Related]
2. Multi-modality treatment of primary nonresectable intrahepatic cholangiocarcinoma with 131I anti-CEA--a Radiation Therapy Oncology Group Study.
Stillwagon GB; Order SE; Klein JL; Leichner PK; Leibel SA; Siegelman SS; Fishman EK; Ettinger DS; Haulk T; Kopher K
Int J Radiat Oncol Biol Phys; 1987 May; 13(5):687-95. PubMed ID: 3032877
[TBL] [Abstract][Full Text] [Related]
3. Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center.
Abrams RA; Pajak TF; Haulk TL; Flam M; Asbell SO
Cancer J Sci Am; 1998; 4(3):178-84. PubMed ID: 9612600
[TBL] [Abstract][Full Text] [Related]
4. A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study.
Order S; Pajak T; Leibel S; Asbell S; Leichner P; Ettinger D; Stillwagon G; Herpst J; Haulk T; Kopher K
Int J Radiat Oncol Biol Phys; 1991 May; 20(5):953-63. PubMed ID: 1850722
[TBL] [Abstract][Full Text] [Related]
5. Dosimetry of 131I-labeled antiferritin in hepatoma: specific activities in the tumor and liver.
Leichner PK; Klein JL; Siegelman SS; Ettinger DS; Order SE
Cancer Treat Rep; 1983; 67(7-8):647-58. PubMed ID: 6307515
[TBL] [Abstract][Full Text] [Related]
6. Antiferritin IgG antibody for isotopic cancer therapy.
Order SE; Klein JL; Leichner PK
Oncology; 1981; 38(3):154-60. PubMed ID: 6259569
[TBL] [Abstract][Full Text] [Related]
7. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
Hellman S
J Clin Oncol; 1985 Dec; 3(12):1569. PubMed ID: 2999345
[No Abstract] [Full Text] [Related]
8. Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma.
Leichner PK; Yang NC; Frenkel TL; Loudenslager DM; Hawkins WG; Klein JL; Order SE
Int J Radiat Oncol Biol Phys; 1988 May; 14(5):1033-42. PubMed ID: 2834309
[TBL] [Abstract][Full Text] [Related]
9. Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti-AFP, and anti-CEA in primary liver cancers.
Leichner PK; Klein JL; Fishman EK; Siegelman SS; Ettinger DS; Order SE
Cancer Drug Deliv; 1984; 1(4):321-8. PubMed ID: 6085756
[TBL] [Abstract][Full Text] [Related]
10. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.
Vriesendorp HM; Herpst JM; Germack MA; Klein JL; Leichner PK; Loudenslager DM; Order SE
J Clin Oncol; 1991 Jun; 9(6):918-28. PubMed ID: 2033428
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.
Klein JL; Nguyen TH; Laroque P; Kopher KA; Williams JR; Wessels BW; Dillehay LE; Frincke J; Order SE; Leichner PK
Cancer Res; 1989 Nov; 49(22):6383-9. PubMed ID: 2553255
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in unresectable hepatocellular cancer: Radiation Therapy Oncology Group Study 83-01.
Stillwagon GB; Order SE; Guse C; Leibel SA; Asbell SO; Klein JL; Leichner PK
Int J Radiat Oncol Biol Phys; 1991 Jan; 20(1):65-71. PubMed ID: 1847127
[TBL] [Abstract][Full Text] [Related]
13. 90Yttrium antiferritin--a new therapeutic radiolabeled antibody.
Order SE; Klein JL; Leichner PK; Frincke J; Lollo C; Carlo DJ
Int J Radiat Oncol Biol Phys; 1986 Feb; 12(2):277-81. PubMed ID: 3005201
[TBL] [Abstract][Full Text] [Related]
14. [131I antiferritin in the treatment of hepatoma and Hodgkin's disease].
Cohen Y; Moroz H
Harefuah; 1986 Dec; 111(11):398-9. PubMed ID: 3028919
[No Abstract] [Full Text] [Related]
15. The theoretical implications and experimental and clinical results of radiolabeled antiferritin.
Order SE
Acta Oncol; 1990; 29(6):689-94. PubMed ID: 2223137
[TBL] [Abstract][Full Text] [Related]
16. [Effect of radio-immunochemotherapy-using antiferritin antibody combined with anthracycline drugs on hepatocellular carcinoma cell].
Une Y; Sato Y; Alam S; Nagabuchi E; Hata Y; Uchino J
Gan To Kagaku Ryoho; 1993 Jan; 20(1):161-3. PubMed ID: 8380685
[No Abstract] [Full Text] [Related]
17. Use of isotopic immunoglobulin in therapy.
Order SE; Klein JL; Ettinger D; Alderson P; Siegelman S; Leichner P
Cancer Res; 1980 Aug; 40(8 Pt 2):3001-7. PubMed ID: 6249495
[TBL] [Abstract][Full Text] [Related]
18. Variable low dose rate irradiation (131I-anti-CEA) and integrated low dose chemotherapy in the treatment of nonresectable primary intrahepatic cholangiocarcinoma.
Stillwagon GB; Order SE; Haulk T; Herpst J; Ettinger DS; Fishman EK; Klein JL; Leichner PK
Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1601-5. PubMed ID: 1657845
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment.
Herpst JM; Klein JL; Leichner PK; Quadri SM; Vriesendorp HM
J Clin Oncol; 1995 Sep; 13(9):2394-400. PubMed ID: 7666099
[TBL] [Abstract][Full Text] [Related]
20. Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease.
Lenhard RE; Order SE; Spunberg JJ; Asbell SO; Leibel SA
J Clin Oncol; 1985 Oct; 3(10):1296-300. PubMed ID: 4045523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
